HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.K. questions NBTY acquisition

This article was originally published in The Tan Sheet

Executive Summary

The U.K. trade regulator says NBTY's acquisition of natural food and ingredients retailer Julian Graves potentially could hinder competition in the nuts, seeds and dried fruit market, and referred the deal for review to its Competition Commission. Because NBTY owns Holland & Barrett, the leading U.K. health food products retailer, the Office of Fair Trading said March 20 it did not receive "sufficient evidence" that other retailers currently adequately constrain NBTY's influence on competition in this area. NBTY and Julian Graves also overlap in vitamins, minerals and supplements sales, but OFT ruled out competition concerns because Julian Graves "sells only limited quantities." Ronkonkoma, N.Y.-based NBTY, which is acquiring Julian Graves through its NBTY Europe subsidiary for approximately $25 million, said it expects the commission's decision by Sept. 3 (1"The Tan Sheet" Sept. 22, 2008, p. 14)

You may also be interested in...



U.K. Play Marks Another NBTY Move Felt By Ingredient Suppliers Everywhere

NBTY increases its influence on competition in the vitamin and dietary supplement ingredient supply market with its acquisition of U.K. natural foods retailer Julian Graves

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS135674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel